AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03488212 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Behavioral Weight Loss Intervention
Description: For 3 months, participants receive: a weekly online lessons for training in behavioral skills for losing weight; online self-monitoring of daily weight, diet, and physical activity; weekly feedback on the self-monitoring record.
Study NCT01798537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neomycin Colistin Nystatin Vancomycin
Description: All participating study arm patients will receive SDD from admission to discharge
Study NCT01858909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Administration via oral or via a nasogastric tube followed by 20mL saline
Study NCT03488212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Intervention
Description: For 3 months, participants receive: a weekly online lessons for training in behavioral skills for losing weight; online self-monitoring of daily weight, diet, and physical activity; weekly feedback on the self-monitoring record.
Study NCT03488212 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention for Weight Loss Maintenance and Weight Gain Prevention
Description: After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive 9 months of: monthly online newsletters with educational information pertaining to healthy weight, diet, and physical activity habits.
Study NCT03488212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly Lessons and Feedback Intervention for Weight Loss Maintenance and Weight Gain Prevention
Description: After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive 9 months of: monthly online lessons for training in behavioral skills for maintaining weight loss and preventing weight gain; online self-monitoring of daily weight, diet, and physical activity; monthly feedback on the self-monitoring record.
Study NCT03488212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Refresher Courses for Weight Loss Maintenance and Weight Gain Prevention
Description: After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive two month-long refresher courses with weekly online lessons for training in behavioral skills for maintaining weight loss and preventing weight gain; online self-monitoring of daily weight, diet, and physical activity; weekly feedback on the self-monitoring record; weekly challenges focuses on specific behavior change and weight loss goals.
Study NCT02862015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX or Gemcitabine based chemotherapy
Description: As a standard palliative chemotherapy, FOLFIRINOX or Gemcitabine based chemotherapy will be treated to the patients.
Study NCT02074150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients.~Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs.
Study NCT03080558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Use of Indocyanine Green during Rectal shaving by laparoscopy.
Study NCT02165319 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Barrel
Description: Barrel-shaped endotracheal tube will be used during general anesthesia.
Study NCT02074150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Gadolinium .1cc/ diluted with .9ccNS subdermally with ASIS Device for 30 patients.~Total cumulative Persistent % of Gadolinium subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs.
Study NCT02074150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
Study NCT02165319 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tapered
Description: Tapered-shaped tube will be used during general anesthesia.
Study NCT01193491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-493
Description: Capsules, ascending dose, multiple schedules
Study NCT03332225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with Placebo
Study NCT01559584 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ultraviolet A (UVA)
Description: 0.5% solution of 8-methoxypsoralen (MOP) will be applied 20 minutes before UVA exposure (315-400nm).~UVA sessions will be carried out twice weekly aiming to achieve a phototoxic reaction, in the form of erythema and vesiculation. Once a phototoxic reaction will be achieved, the patient will be asked to rest until the reaction subsides and then resume the phototherapy sessions.
Study NCT01559584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: One monthly injections of intralesional triamcinolone acetonide
Study NCT04629105 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Longeveron Mesenchymal Stem Cells (LMSCs)
Description: Longeveron Mesenchymal Stem Cells (LMSCs)
Study NCT04629105 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00239694 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine
Description: One time preventative vaccine
Study NCT00239694 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Vaccine
Description: One time preventative vaccine
Study NCT02184234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antistax film coated tablets
Study NCT04023266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous N-Acetylcysteine
Description: Intravenous N-acetyl cysteine bolus and infusion as described in the experimental arm.
Study NCT01844063 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Conventional plus BM-MSC treatment
Description: Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times).
Study NCT01844063 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Conventional plus UC-MSC treatment
Description: Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times)
Study NCT01844063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Received conventional treatment including:~A.antiviral drugs(Entecavir,Lamivudine,Adefovir dipivoxil,et al); B.Hepatoprotective drugs(Ademetionine1,4-butanethiosulfonate for Injection, Reduced Glutathione for Injection,Polyene Phosphatidylcholine, et al); C.Plasma.
Study NCT04126993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab,
Description: Camrelizumab+ Apatinib test group: intravenous injection once every three weeks, Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
Study NCT02074150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 6
Description: Efficacy of Botox intramuscularly at Week 6, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
Study NCT02074150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 12,
Description: Efficacy of Botox intramuscularly at Week 12, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
Study NCT04126993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib
Description: Apatinib single drug control group: Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
Study NCT04126993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib single drug control group: Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
Study NCT00611598 — intervention group
Intervention type: OTHER
Intervention: Blood draw and Questionnaires
Description: Pt will have three green top tubes of blood drawn. The questionnaire will be filled out by the study subject. This may be completed at home and mailed in a provided stamped addressed envelope if the patient prefer, or obtained by phone interview with a research assistant.
Study NCT02074150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 18
Description: Efficacy of Botox intramuscularly at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
Study NCT03042572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic Mesenchymal Stromal Cell
Description: Intramuscular allogeneic BM-MSC injection: MSCs will be extracted from BM of healthy volunteers, expanded with human platelet lysate, and stored. Patients will receive intramuscular allogeneic BM-MSC injections at 30 sites in the lower leg of the ischemic limb. Blinded syringes are provided and cell suspensions will be injected intramuscularly by an experienced operator into multiple sites (30 sites, 1-1.5cm in depth, volume of 1.0mL containing 5\*10\^6 MSC per site; total 150\*10\^6 BM-MSCs) in the ischemic lower extremity. Injections will be performed under IV analgesia (fentanyl) and sedation (midazolam) if necessary.
Study NCT03042572 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular placebo injections. Patients will receive intramuscular placebo injections at 30 prespecified sites in the lower leg of the ischemic limb. Blinded syringes are provided and will be injected intramuscularly by an experienced operator into multiple sites (30 sites, 1-1.5cm in depth, volume of 1.0mL placebo per site) in the ischemic lower extremity. Injections will be performed under IV analgesia (fentanyl) and sedation (midazolam) if necessary.
Study NCT04246359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab Biosimilar
Description: To evaluate the short-term objective efficacy of HLX01 combined with Pegylated Interferon α-2b in patients with advanced idolent B-cell lymphoma.
Study NCT04246359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon α-2b
Description: To evaluate the short-term objective efficacy of HLX01 combined with Pegylated Interferon α-2b in patients with advanced idolent B-cell lymphoma.
Study NCT02778477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06423264
Description: Multiple ascending dose of PF-06423264
Study NCT02074150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 24
Description: Efficacy of Botox intramuscularly at Week 24, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
Study NCT02778477 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple dose of placebo
Study NCT01005563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beef/Pork
Description: Participants consuming diet containing 10, 20 or 30% dietary protein with beef/pork as the predominate sources of protein
Study NCT01005563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soy/Legumes
Description: Participants consuming diet containing 10, 20, or 30% dietary protein with soy/legumes as the predominate sources of protein.
Study NCT02074150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 30
Description: Efficacy of Botox intramuscularly at Week 30, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
Study NCT02704637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HS-1000
Description: HeadSense (HS)-1000 device, a proprietary non-invasive brain monitor, is expected to safely and accurately monitor physiological signs of the brain with minimal discomfort to patients, providing information about normal or abnormal brain-related conditions and providing decision-making support for physicians
Study NCT00882375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine administered using novel NRT user instructions
Study NCT00882375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered using novel NRT user instructions
Study NCT01451840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia
Study NCT01451840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alkalinized lidocaine
Description: Administration of alkalinized lidocaine in the endotracheal tube cuff
Study NCT01815840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Vismodegib 150 mg hard gelatin capsule orally once daily
Study NCT01815840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Vismodegib placebo orally once daily
Study NCT01085877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol, 25 mcg
Description: Single dose of vaginal tablet containing 25 mcg estradiol (Production site A) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site B)
Study NCT01085877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol, 25 mcg
Description: Single dose of vaginal tablet containing 25 mcg estradiol (Production site B) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site A)
Study NCT01336413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnenolone
Description: Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial
Study NCT01336413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same as active comparator, except placebo dispensed.
Study NCT03781778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention (resistant starch)
Description: Eat foods with resistant starch
Study NCT03781778 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention (regular starch)
Description: Eat foods with regular corn starch
Study NCT03781778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03781778 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01832155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha yoga
Description: Hatha yoga poses that were specifically designed by a group of yoga experts for older adults with knee osteoarthritis. Program included physical poses and sequence that focus on strengthening the lower extremities, and relaxation techniques.
Study NCT01832155 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hatha Yoga
Description: The same intervention was provided to the wait-list control group at the end of 8 weeks when the intervention completed their intervention classes.
Study NCT01431053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: Aspirin 50mg po daily
Study NCT01431053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Exemestane 25mg po daily
Study NCT01431053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane 25mg po daily
Study NCT00225498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziprasidone vs risperidone or olanzapine
Description: ziprasidone target dose is 160 mg/day risperidone target dose is 4 mg/day olanzapine target dose is 20 mg/day
Study NCT00225498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ziprasidone vs risperidone or olanzapine
Description: ziprasidone target dose is 160 mg/day risperidone target dose is 4 mg/day olanzapine target dose is 20 mg/day
Study NCT01957813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: Peer educators will be trained using existing materials to deliver accurate messaging on FP/dual method use, during individual encounters and in group sessions.~Screening for unmet FP need in DICs Providing job aids to FP counselors Expanding FP methods with intra-uterine contraceptive devices (IUCD) and implants Time change in DIC hours of operation
Study NCT01957813 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Health Services
Description: Peer education and health services
Study NCT03139123 — intervention group
Intervention type: OTHER
Intervention: Hemodynamic monitoring during passive leg raising
Description: Measurement of hypotensive episodes related to preload dependance.
Study NCT04679194 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mana 312
Description: Mana 312 is a cellular product comprised of expanded T cells derived from allogeneic donor leukocytes that have been stimulated with monocyte derived dendritic cells pulsed with tumor-associated antigen (TAA) peptide mixes for 3 antigens: Wilms Tumor gene 1 (WT 1), the preferentially expressed antigen of melanoma (PRAME), and Survivin.~Each Mana 312 product is specifically matched for an individual subject and will be manufactured from leukocytes from the same donor who provided stem cells to that subject for their current allogeneic hematopoietic stem cell transplantation (HSCT).
Study NCT03492606 — intervention group
Intervention type: PROCEDURE
Intervention: Samples
Description: lumbar puncture, blood and CSF samples, SNPs analysis
Study NCT01000259 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Samples are analyzed in laboratory studies
Study NCT00728091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satavaptan
Description: tablets
Study NCT00728091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablets
Study NCT01888224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: Isotretinoin Capsules,40 mg
Study NCT01888224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Isotretinoin Capsules,40 mg
Study NCT01222780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marqibo
Description: Marqibo® intravenously (IV) over 60 minutes (+ 10 minutes) every 7 days (+ 3 days) for 4 consecutive weeks (day 1, 8, 15, 22) for a 28-day treatment cycle
Study NCT03114332 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcutaneous Drain
Description: A closed drainage system for the subcutaneous tissue was used (Redivac) through a separate stab wound. Drains were left in place for 24 h or until drainage was less than 50 ml.
Study NCT02914665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elamipretide
Description: 20 mg elamipretide administered intravenously once daily for 7 consecutive days
Study NCT02914665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intravenously once daily for 7 consecutive days
Study NCT00108316 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluoxetine (Liquid Prozac)
Study NCT01672424 — intervention group
Intervention type: OTHER
Intervention: Ice Chips
Description: 11 ounces of ice chips given to the laboring parturient
Study NCT01672424 — intervention group
Intervention type: OTHER
Intervention: Protein Drink
Description: Patients will receive 11 ounces of a protein shake which contains 30 grams of protein
Study NCT02172378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium inhalation capsules
Study NCT02172378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation capsules
Study NCT02861898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-arterial Cetuximab
Study NCT02861898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-arterial Mannitol
Study NCT01787578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sobetirome
Description: 50 mcg or 100 mcg once-daily oral
Study NCT02608112 — intervention group
Intervention type: DRUG
Intervention: Methotrexate
Description: Administered as per investigator's discretion. Investigator could also suggest any other csDMARDs instead of methotrexate.
Study NCT02608112 — intervention group
Intervention type: DRUG
Intervention: Tocilizumab
Description: Tocilizumab treatment will be administered SC at the discretion of the investigator in accordance with local clinical practice and local labelling.